Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05069623
Other study ID # VB-D-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 1, 2021
Est. completion date May 30, 2023

Study information

Verified date April 2024
Source Nykode Therapeutics ASA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). tThree dose levels will be tested. IM administrations 21 days apart. Part 1 is a dose escalation phase and Part 2 is a dose expansion phase. In Part 2 a selected dose will be tested further in additional healty volunteers.


Description:

This is an open label, dose escalation, and dose expansion study designed to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 or COVID-19 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). Part 1 is a dose escalation phase and Part 2 is a dose expansion phase and both vaccine candidates, ie, VB10.2129 (C1) and VB10.2210 (C2) will be tested. Part 1 consist of two arms: one arm with each vaccine candidate and each arm investigating three escalating dose levels. 10 subjects previously vaccinated with an mRNA vaccine will be enrolled at each dose level. Each subject will receive two vaccinations 21 days apart (Day 0 and Day 21). In Part 2 is a dose expansion phase with one arm for each candidate; VB10.2129 and VB10.2210, in previously vaccinated healthy subjects only. The dose to be investigated will be selected based on safety and inital immune response data from Part 1. All subjects will be folowed for up to 1 year after the first vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date May 30, 2023
Est. primary completion date December 16, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Main inclusion criteria: - Give informed consent by signing the Informed Consent Form (ICF) SARS CoV 2 vaccination status for Part 1: 1. VB10.2129 (C1): have received 2 or 3 doses of an approved mRNA SARS CoV 2 vaccine, minimum 4.5 months (20 weeks) prior to Visit 1. 2. VB10.2210 (C2): have received 2 doses (primary vaccination) or 3 (primary and boost) doses of an approved mRNA SARS CoV 2 vaccine, minimum 8 weeks prior to Visit 1. SARS CoV 2 vaccination status for Part 2: VB10.2129 (C1) and VB10.2210 (C2) Vaccination status prior to Visit 1 will be decided based on data from Part 1. - Willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (eg, local law and regulations [county specific lock down rules] regarding COVID-19), and other requirements of the study. - Healthy, in the clinical judgement of the Investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests (blood chemistry, haematology, and urine chemistry) at Visit 0 (Screening). - Women of childbearing potential (WOCBP) must have a negative pregnancy test and must agree to practice a highly effective form - Agree not to be vaccinated with any other vaccine during the study until 28 days after receiving the last study vaccination - Negative rtPCR-test for SARS-CoV-2 Main exclusion criteria: - Have had any acute illness with or without fever, within 72 hours prior to the first vaccination - Symptoms of upper respiratory infection, fever, persistent cough, shortness of breath, runny nose and breathing difficulties - Breastfeeding or who plan to breastfeed during the study - Have a known allergy, hypersensitivity, or intolerance to aminoglycosides - Had any clinically significant or chronic medical condition or any major surgery within the past 5 years which - Have any surgery planned during the study - Had any chronic use of any systemic medications, including immunosuppressant's, oral corticosteroids or other immune-modifying drugs, within the 12 months prior to Screening - Received any vaccination within the 28 days prior to Screening - Received any prescription medicines (except hormonal contraception for WOCBP) within 14 days prior to Visit 0 (Screening) or over the counter medicines (except paracetamol and acetaminophen at a dose of (=2 grams/day)) within 48 hours of Visit 0. - Have a known history or a positive test of HIV 1 or 2, Hep B, or Hep C - Have a positive rtPCR test for SARS-CoV-2 within 2 days of Screening - Documented history of previous infection with SARS-CoV-2 and/or who have the presence of serum Ab indicative of a previous SARS-CoV-2 infection - Have a history of hypersensitivity or have had a serious reaction to a previous vaccination - Have any abnormality or permanent body art (eg, tattoo) that, would obstruct the ability to observe local reactions at the injection site. - Have a condition known to put them at high risk for severe COVID-19, including those with any of the following risk factors: Hypertension, diabetes mellitus, chronic pulmonary disease, asthma, chronic liver disease, known stage 3 or worse chronic kidney disease - Anticipating the need for immunosuppressive treatment within the next 6 months. Other inclusion or exclusion criteria may apply.

Study Design


Intervention

Biological:
VB10.2129
0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
VB10.2210
3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0

Locations

Country Name City State
Norway Haukeland University Hospital, Klinisk Forskningspost Bergen
Norway Oslo University Hospital Ullevål Sykehus, Dept. Infection Diseases Oslo

Sponsors (2)

Lead Sponsor Collaborator
Nykode Therapeutics ASA Vaccibody AS

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and frequency of local and systemic solicited adverse events (AEs) As self reported in eDiary Day 0 to Day 7 days after each vaccination
Primary Incidence and frequency of local and systemic unsolicited AEs As elicited by investigator Day 0 to Day 49
Primary Incidence and frequency of serious AEs (SAEs) As elicited by investigator Day 0 to 1 year
Secondary Humoral responses against SARS-CoV-2 Number participants with increase in Ab titre and neutralizing Ab responses after first and second vaccine and long term responses (VB10.2129) Day 0 (before Dose 1) up to 1 year
Secondary Cellular responses (T-cell responses) to SARS-CoV-2 RBD epitopes by ELISpot Number of participants with change from baseline in Antigen-Specific T-cell cytokine production and long term T-cell responses Day 0 (before Dose 1) up to 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure